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Bone morphogenetic protein type 2 (BMP-2) is a potent local factor, which promotes bone formation and has been used as an osteogenic supplement for mesenchymal 
stem cells. Objectives: This study evaluated the effect of a recombinant BMP-2 as well 
as the endogenous BMP-4 and BMP-7 in the osteogenic differentiation of adipose-derived 
stem cells (ASCs) in medium supplemented with ascorbate and β-glycerophosphate. 
Material and Methods: Human ASCs were treated with osteogenic medium in the presence 
(ASCs+OM+BMP-2) or absence (ASCs+OM) of BMP-2. The alkaline phosphatase (ALP) 
activity was determined and the extracellular matrix mineralization was evaluated by Von 
Kossa staining and calcium quantification. The expressions of BMP-4, BMP-7, Smad1, 
Smad4, and phosphorylated Smad1/5/8 were analyzed by western blotting. Relative mRNA 
expressions of Smad1, BMP receptor type II (BMPR-II), osteonectin, and osteocalcin were 
evaluated by qPCR. Results: ASCs+OM demonstrated the highest expression of BMP-4 
and BMP-7 at days 21 and 7, respectively, the highest levels of BMPR-II mRNA expression 
at day 28, and the highest levels of Smad1 mRNA at days 14 and 28. ASCs+OM+BMP-2 
demonstrated the highest levels of Smad1 mRNA expression at days 1, 7, and 21, the highest 
expression of Smad1 at day 7, the highest expression of Smad4 at day 14, the highest ALP 
activity at days 14 and 21, and expression of phosphorylated Smad1/5/8 at day 7. ASCs+OM 
and ASCs+OM+BMP2 showed similar ALP activity at days 7 and 28, similar osteonectin 
and osteocalcin mRNA expression at all time periods, and similar calcium depositions at 
all time periods. Conclusions: We concluded that human ASCs expressed endogenous 
BMP-4 and BMP-7. Moreover, the supplementation of ASCs with BMP-2 did not increase 
the level of osteogenic markers in the initial (ALP activity), intermediate (osteonectin and 
osteocalcin), or final (calcium deposition) phases, suggesting that the exogenous addition 
of BMP-2 did not improve the in vitro osteogenesis process of human ASCs.
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INTRODUCTION
Mesenchymal stem cel ls (MSCs) have 
been receiving considerable attention in bone 
regeneration, both for tissue engineering or cellular 
therapy. These cells are capable of self-renewal or 
differentiation into multi-lineage cells, including 
osteoblasts and condroblasts, under the appropriate 
conditions. MSCs have been isolated from different 
tissues, such as bone marrow, dental pulp, fat, 
and gingiva7,18,26,34,36. Adipose-derived stem cells 
(ASCs) represent one interesting cellular option for 
clinical applications since these cells are available in 
large amounts, are easily accessible and isolated, 
and they demonstrate a fast attachment and 
proliferation in culture36.
Bone morphogenetic proteins (BMPs) belong to 
the transforming growth factor b (TGF-b) super-
family and were identified by their ability to induce 
bone formation at ectopic sites28. In particular, 
BMP-2, BMP-4, and BMP-7 have been associated 
with bone development20. BMP-2 has been used 
for treatment of bone defects in orthopedic, spine, 
and maxillofacial surgeries1,5. Interestingly, it was 
observed during the fracture repair that an increase 
of BMP-4 and BMP-7 occurs in response to the 
presence of BMP-227, and it was suggested that 
BMP-4 and BMP-7 might be able to substitute each 
other during bone healing, as has been shown in 
other tissues where these BMPs are co-expressed10. 
Therefore, the co-expression of a panel of BMPs 
exert strong synergy, meaning that combination of 
certain BMPs may be more efficacious than single 
BMP to stimulate osteogenic differentiation, and 
different BMPs may act at different nodal points of 
osteogenesis5,20. Besides the exogenous BMPs, it is 
important to consider the possibility and the effects 
of biologically active endogenous BMPs expressed 
by human MSCs. Seib, et al.22 (2009) observed 
that bone marrow-derived stem cells promoted 
osteogenesis by endogenous BMP-2, BMP-4, and 
BMP-6.
Classical signaling pathway for BMPs begins 
with the binding of BMP to a dimeric complex of 
transmembrane serine-threonine kinase receptors, 
the type I and type II receptors. Type I receptors 
include BMP receptors (BMPRs) -IA, -IB, and activin 
receptor type 1 (ACTR1), while type II receptors 
include BMPR-II, ACTR2, and -2b, which are 
constitutively active kinases. These BMPRs subtypes 
have different BMP affinities and form receptor 
complexes prior to or after BMP binding, which is 
thought to regulate BMP signaling (Smad-dependent 
versus Smad-independent). Heteromeric receptor 
complexes comprising type I and II receptors 
lead to ligand-induced phosphorylation of type I 
receptors. Following the activation of this receptor, 
receptor kinases phosphorylate the transcription 
factors Smad1, 5 or 8 that subsequently form 
heteromeric complexes with Smad4 and activate 
the expression of target genes in the nucleus9,21,23. 
Reports have shown that mitogen-activated 
protein kinase (MAPK)12 and phosphatidylinositol 
3-kinase (PI-3K)16,22 activity are critical switches 
for osteogenic differentiation, indicating that other 
pathways, other than the Smad pathway, regulate 
the mesenchymal stem cells differentiation after 
BMP exposure.
The most usual supplementation for in vitro 
osteogenic differentiation includes ascorbate, 
β-glycerophosphate, and dexamethasone17,31,36. 
Several studies have used BMP-2 instead of 
dexamethasone for osteogenic induction14,22,32. 
Differently, some reports have demonstrated 
that in vitro and in vivo treatments of ASCs with 
BMP-2 had no consistent effect on osteogenic 
differentiation6,35. Therefore, this study evaluated 
the effect of a recombinant BMP-2 as well as the 
endogenous BMP-4 and BMP-7 in the osteogenic 
differentiation of adipose-derived stem cells (ASCs) 
in medium supplemented with ascorbate and 
β-glycerophosphate.
MATERIALS AND METhODS
Reagents
Antibiotics/antifungic agentes were purchased 
from Cultilab (São Paulo, SP, Brazil). Ascorbate, 
β-glycerophosphate, BMP-2 (recombinant human 
BMP-2), eosin, paraformaldehyde, r-nitrophenol 
phosphate (ρNPP), and silver nitrate were obtained 
from Sigma-Adrich (St. Louis, MO, USA). α-modified 
eagle's minimal essential medium (αMEM modified) 
and Dulbecco’s modified Eagle’s medium (DMEM) 
were from Nutricell (São Paulo, SP, Brazil). Fetal 
bovine serum, SuperScript™ III, and Trizol® were 
purchased from Invitrogen (Carlsbad, CA, USA). 
Kit Calcium Assay was from BioAssay Systems 
(Hayward, CA, USA). Antibodies anti -BMP4 
(MAB1049), -BMP7 (MAB4350), -β actin (04-1116), 
-Smad1 (05-1459), -phosphorylated Smad1/5/8 
(AB3848), -Smad4 (04-1033), anti-rabbit, anti-goat 
and anti-mouse peroxidase-conjugated antibodies, 
and Immobilon-P membranes were obtained 
from Millipore (Danvers, MA, USA). enhanced 
chemiluminescence Pierce eCL was from Thermo 
scientific (Rockford, IL, USA). Step One® detection 
system and SYBR® Green PCR Master Mix were 
purchased from Applied Biosystems (Carlsbad, CA, 
USA). All chemicals were of analytical grade.
Isolation and culture of human adipose-
derived stem cells
After approval by the Institutional Human ethics 
Committee (No. 194/06 for adipose-derived stem 
cells and No. 568/10 for human osteoblasts) and 
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with the understanding and written consent of the 
voluntaries, human lipoaspirate tissues from three 
healthy patients (average age 21), with normal 
body mass indexes, non-smokers, and not taking 
any medication, were processed to isolate the ASCs, 
as described by Zuk, et al.36 (2001). The ASCs were 
sub-cultured and used at passage 3, according to 
the following groups: ASC+OM: Osteogenic medium 
(OM) (DMeM supplemented with 250 µM ascorbate 
and 10 mM β-glycerophosphate); ASCs+OM+BMP2: 
OM with 50 ng/mL BMP-2. MC3T3-e1 pre-
osteoblasts subclone 4 (American Type Culture 
Collection, Manassas, VA, USA, 2593™) were used 
as the positive control for the determination of the 
alkaline phosphatase activity, the evaluation of 
matrix mineralization, and for the western blotting 
assays. MC3T3-e1 cells were cultured according to 
the recommendations in αMEM modified with 50 
µg/mL ascorbate and 10 mM β-glycerophosphate33. 
Human osteoblasts were used as the positive 
control in the qPCR experiments. Human osteoblast 
explant cultures13 were obtained from three patients 
through biopsies of cortical-porous bone tissue 
from the mandible, using dental implant drills. 
Human osteoblasts (passage 6) were cultured with 
OM. Culture media were supplemented with 10% 
(v/v) fetal bovine serum and 1% (v/v) antibiotic/
antifungic.
Determination of alkaline phosphatase 
activity
MC3T3-e1 and ASCs (9.4x104 cells/well in 
24-well plates) were cultivated for 7, 14, 21, 
and 28 days. Trizol® was used for total protein 
extraction, and the concentrations were determined 
according to the Lowry’s method19. ALP activity was 
determined by releasing r-nitrophenol (ρNP) from 
r-nitrophenol phosphate (ρNPP). Concisely, 0.5 
mL of diethanolamine buffer (1.02 M, pH 9.8, 0.6 
mM magnesium chloride) and 0.5 mL of ρNPP were 
incubated for 2 min at 37°C. Afterward, 0.1 mL of 
the extracted protein was added and incubated at 
37°C. Following 30 min, 1 mL of 3 N NaOH was used 
to stop the reaction. Absorbances were measured 
(Infinite M200, TECAN, Salzburg, Grödig, Austria) at 
405 nm, and the ALP activity was calculated from a 
ρNP standard curve and all values were normalized 
against the total protein concentration.
Evaluation of matrix mineralization
Von Kossa staining determined the presence of 
phosphate at the extracellular matrix. MC3T3-e1 
and ASCs (2x104 cells/well on a 96-well plates) were 
cultivated for 21 days. Cells were fixed for 1 h with 
3% (v/v) aqueous paraformaldehyde and stained 
with 1% (w/v) silver nitrate under light exposure 
for 1h, and counterstained with eosin.
MC3T3-e1 and ASCs (2x104 cells/well on 96-well 
plates) were cultivated for 5, 12, 23, and 32 days, 
for the calcium quantification at the extracellular 
matrix. Cells were harvested in 200 µL of 0.1 N HCl 
at 4°C for 4 h and centrifuged at 10,000 x g for 5 
min. The Kit Calcium Assay was used for measuring 
the supernatant total calcium.
western blotting
MC3T3-e1 and ASCs (9.4x104 cells/well on 
24 well-plates) were cultivated for 7, 14, 21, 
and 28 days. Following cells lysis, the protein 
quantification was performed. For the western 
blotting experiments, 5 μg of denatured protein were 
loaded onto an SDS/polyacrylamide gel. Proteins 
were transferred to Immobilon-P membranes, 
which were incubated overnight with anti -Smad1 
(1:500), -phosphorylated Smad1/5/8 (1:500), 
-Smad4 (1:1000), -BMP4 (1:500), -BMP7 (2 
μg/mL), or -β actin (1:2000) antibodies. After 
incubation with each corresponding secondary 
antibody, the enhanced chemiluminescence Pierce 
eCL substrate was used for detection, according to 
the manufacturer’s protocol.
qPCR
Human osteoblasts and ASCs (9.4x104 cells/well) 
were cultured for 1, 7, 14, 21, and 28 days on 24-well 
plates. Total RNA was isolated with Trizol® reagent, 
and cDNA transcriptions were performed using 
oligo (dT) primers and SuperScript™ III. Step One® 
detection system and SYBR® Green PCR Master Mix 
were used for the qPCR. The comparative threshold 
cycle (Ct) method was used in order to quantify 
changes in the Smad1, BMPR-2, Osteonectin, and 
Osteocalcin gene expression between the control 
(human osteoblasts) and treated ASCs. The fold 
difference between the control and treatments 
was calculated according to 2-∆∆Ct, where 
∆∆Ct=(∆Ct control) - (∆Ct treatment) and ∆Ct=(Ct 
target gene) - (Ct internal control, ribosomal 18 
s). BMPR-II mRNA expression: Primer forward 
5’-3’ TGAAAAGATCAAGAAACGTGTGAAA. Primer 
reverse 5’-3’ GCCCTGTTACTGCCATTATTGTT; 
Smad1 mRNA expression: Primer forward 
G G G A C TG C C TC ATG TC ATTTA C T.  P r i m e r 
r e v e r s e  C A G A C C T C C TT C T G C TT G G A A ; 
Osteoca lc in  mRNA re la t ive  express ion: 
Primer forward AGGGCAGCGAGGTAGTGAAG. 
Primer reverse AACTCGTCACAGTCCGGATTG; 
Osteonectin mRNA expression: Primer forward 
CGGGTGAAGAAGATCCATGAG. Primer reverse 
CTGCCAGTGTACAGGGAAGATG. 
Statistical analysis
All experiments were performed in triplicate to 
confirm the reproducibility of the results. The results 
of the ALP activity and calcium quantification in all 
groups were compared through non-parametric 
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one-way analysis of variance (ANOVA) followed by 
the Student Newman-Keuls (SNK) post hoc test. 
Results of mRNA relative expression in all groups 
were compared through the Student’s t test. 
Statistical analyses were performed comparing all 
treatments for each time period separately using 
the GraphPad Prism 4 software (Graph Pad Software 
Inc, San Diego, CA, USA) at a 95% confidence 
interval.
RESULTS
BMP-2 improved the alkaline phosphatase 
activity
ASCs+OM and ASC+OM+BMP2 demonstrated 
similar ALP activities, and MC3T3-e1 cells (positive 
control) showed the highest activity (r=0.0004) 
at day 7. ASCs+OM+BMP2 up-regulated the ALP 
activity compared to ACS+OM and MC3T3-e1 at 
day 14 (r=0.00379). At day 21, ASCs+OM+BMP2 
and MC3T3-e1 demonstrated the highest activities 
(r=0.0087). There was no statistically significant 
difference among the groups at day 28 (r>0.05) 
(Figure 1).
BMP-2 did not improve the calcium at the 
extracellular matrix
Von Kossa staining demonstrated that all groups 
presented phosphate at the extracellular matrix at 
day 21 (Figure 2A-C).
At day 5, calcium deposition was not observed 
at the extracellular matrix. At day 12, MC3T3-e1 
demonstrated the highest calcium amount 
(r<0.0001), ASCs+OM and ASCs+OM+BMP2 
showed similar results. There was no statistically 
significant difference among the groups (r>0.05) 
at days 23 and 32 (Figure 2D).
Expression of osteoblast-related proteins
ASCs+OM+BMP2 expressed more Smad1 when 
compared to MC3T3-e1 and ASCs+OM at day 7. At 
days 14 and 21, all groups demonstrated similar 
Smad1 expressions. ASCs+OM demonstrated the 
lowest expression at day 28 (Figure 3).
Only MC3T3-e1 expressed phosphorylated 
Smad1/5/8 at day 7. All groups demonstrated 
similar expression of these proteins at day 14. 
At day 21, ASCs+OM+BMP2 expressed more 
than ASCs+OM, while MC3T3-e1 stopped these 
expressions. All groups had no expression of these 
phosphorylated proteins at day 28 (Figure 3).
ASCs+OM showed the highest Smad4 expression 
at day 7. At day 14, MC3T3-e1 demonstrated the 
highest expression followed by ASCs+OM+BMP2 
and then by ASCs+OM. MC3T3-e1 demonstrated 
the highest level of Smad4 at day 21, followed by 
ASCs+OM and then by ASCs+OM+BMP2. At day 28, 
MC3T3-e1 showed the highest expression, while 
ASCs+OM and ASCs+OM+BMP2 demonstrated 
similar levels of Smad4 (Figure 3).
All groups had no expression of BMP-4 at day 
7. At day 14, ASCs+OM and ASCs+OM+BMP2 
demonstrated similar expressions, while MC3T3-e1 
had no expression. ASCs+OM demonstrated 
the highest BMP-4 expression followed by 
ASCs+OM+BMP2 and then MC3T3-e1 at day 
Figure 1- Alkaline phosphatase (ALP) activity. Enzymatic 
activity at days 7, 14, 21, and 28. Different letters refer to 
statistical significant differences (ANOVA/SNK, ρ<0.05)
Figure 2- Extracellular matrix mineralization. A) Von Kossa staining. Adipose-derived stem cells (ASCs) with osteogenic 
medium (OM). Bar=500 μm; B) ASCs with OM supplemented with BMP-2; C) MC3T3-E1 cells (positive control); D) Calcium 
quantification at days 12, 23, and 32. Different letters refer to statistical significant differences (ANOVA/SNK, ρ<0.05)
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21. Figure 3 did not show differences between 
ASCs+OM and ASCs+OM+BMP2 groups at day 28, 
while MC3T3-e1 demonstrated a weak expression.
ASCs+OM+BMP2 expressed the lowest BMP-7 
levels at day 7. The expressions were similar for 
all groups at day 14. At day 21, ASCs+OM+BMP2 
showed the highest expression of this protein. 
ASCs+OM BMP-7 expressions were smaller than 
the other groups at day 28 (Figure 3).
Relative expression of osteoblast-related 
mRNA
Figure 4A shows that BMPR-II relative mRNA 
express ions  were  s imi la r  fo r  ASCs+OM and 
ASCs+OM+BMP2 (ρ>0.05) at days 1, 7, 14, and 21. 
At day 28, ASCs+OM demonstrated the highest expression 
(ρ=0.0118).
ASCs+OM+BMP2 showed the highest levels of 
Smad1 relative mRNA expression at days 1 (ρ<0.0001), 
7 (ρ=0.0002), and 21 (ρ=0.0008). ASCs+OM 
demonstrated the highest expressions at days 14 
(ρ=0.0014) and 28 (ρ=0.0003) (Figure 4B).
Osteocalcin and Osteonectin relative mRNA 
expressions were similar for all groups for all time 
periods (ρ>0.05) (Figure 4C and 4D).
DISCUSSION
BMP-2 is considered a potent local factor that 
promotes bone formation1 and has been used as 
an osteogenic supplementation14,22,32. This report 
evaluated the effects of BMP-2 associated with 
ascorbate and β-glycerophosphate to induce 
osteogenic differentiation of human ASCs during 
Figure 3- Expression of osteoblast related proteins. Protein expression evaluated by western blotting, at days 7, 14, 21, 
and 28
Figure 4- mRNA relative expression. A) BMPR-II mRNA expression; B) Smad1 mRNA expression; C) Osteocalcin mRNA 
relative expression; D) Osteonectin mRNA expression. Different letters refer to statistical significant differences (T test, 
ρ<0.05)
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the entire in vitro osteogenic process (day 1 to 32), 
and the effects of endogenous BMP-4 and BMP-7 
in this process. Herein, efforts were made to study 
osteogenic markers, such as ALP activity, Smads, 
BMPR-II, osteonectin, osteocalcin, and calcium 
deposition, as discussed below.
An enzymatic hydrolysis activity of ALP is 
necessary to initiate biological mineralization by 
hydrolyzing β-glycerophosphate, which serves as 
an additional source of phosphate ions25. Some 
proteins are involved in the extracellular matrix 
deposition and mineralization during bone formation, 
such as osteonectin and osteocalcin. Osteonectin 
is an intermediate phase glycoprotein that binds 
calcium and type I collagen with a high affinity. 
Osteocalcin is produced exclusively in bone, dentin, 
and cementum and it represents approximately 20% 
of non-collagenous proteins11. Finally, a functional 
assay of terminally differentiated osteoblasts is the 
extracellular matrix mineralization, which can be 
evaluated by the calcium quantification.
In general, we observed that the supplementation 
with BMP-2 did not increase the levels of osteogenic 
markers in the initial, intermediate, or final phases of 
human ASCs differentiation. Our results demonstrated 
that these cells expressed endogenous BMP-4 and 
BMP-7, and we were encouraged to suggest that 
these endogenous BMPs were biologically active 
due to the observed induction of ALP activity, up-
regulation of osteogenic genes (osteocalcin and 
osteonectin), and increase of calcium deposition in 
cells treated without BMP-2. Conversely, Seib, et al.22 
(2009) observed that human bone marrow-derived 
mesenchymal cells were able to express endogenous 
BMP-4, but not BMP-7. These observed differences 
may be attributed to the different cell lines used.
Herein, the peak of ALP activity, which indicates 
the initial phase of extracellular matrix mineralization, 
occurred at day 7. At that stage, ASCs treated in the 
presence or absence of BMP-2 demonstrated similar 
results, suggesting that BMP-2 supplementation 
did not improve the initial phase of osteogenic 
differentiation, in accordance with Song, et al.24 
(2007) (human bone marrow-derived stem cells) 
and differing from Wang, et al.30 (2010) (rat bone 
marrow stromal cells). It is important to appreciate 
that explanations made with BMPs in human cells 
can be extrapolated to the human system with more 
precision22.
The presence of BMP-2 in medium supplementation 
did not up-regulate the BMPR-II mRNA expression, 
similarly to that found by Wang, et al.30 (2010). We 
also observed a similar expression of osteocalcin 
and osteonectin mRNA relative expression for ASCs 
treated with or without BMP-2. Zuk, et al.35 (2011) 
demonstrated that induction of ASCs with OM 
containing BMP-2 for 7 days significantly augmented 
expression of osteopontin and osteocalcin, and 
decreased ALP and osteonectin gene expressions. 
However, when the exposure time to BMP-2 was 
increased to either 21 or 28 days (the terminal 
differentiation stages of ASCs) any changes to the 
gene expression, attributable to BMP-2 was lost. 
Wan, et al.29 (2006) observed similar osteonectin 
expression in mouse ASCs cultures using control 
medium and osteogenic medium with BMP-2. 
Complementary, our results demonstrated that 
ASCs treated with or without exogenous BMP-2 
showed similar calcium deposition at the extracellular 
matrix, as found by Song, et al.24 (2007) and Zuk, 
et al.35 (2011). Conversely, Beloti and Rosa3 (2005) 
demonstrated that osteoblast differentiation of 
human bone marrow cells did not occur only in the 
presence of ascorbate and β-glycerophosphate. 
Khanna-Jain, et al.15 (2010) observed that the 
addition of BMP-2 or BMP-6 to dexamethasone, 
ascorbic acid, and β-glycerophosphate did not 
enhance osteogenic differentiation of human 
periodontal ligament cells, since they observed that 
neither of the BMPs induced in vitro mineralization, 
despite the increase of ALP activity.
BMP-2 supplementation led to the highest levels 
of Smad1 relative mRNA expression at days 1, 7, and 
21, the highest expression of Smad1 at day 7, and 
the highest expression of Smad4 at day 14. Chang, 
et al.4 (2009) demonstrated that the treatment of 
osteoblast-like cells with BMP-4 increases Smad1/5 
phosphorylation. Aoki, et al.2 (2001) also observed 
that the BMP-4 activation in C2C12 mouse muscle 
myoblast cell line occurs via the Smad pathway. We 
did not observe an association between the BMP-
4 expression and Smads1/5/8 phosphorylation. 
Supporting our results, Seib, et al.22 (2009) 
demonstrated that osteogenesis by endogenous 
BMP-4 and BMP-6 was independent of Smad 
activation and dependent on phosphatidylinositol 
3-kinase (PI-3K) activation in marrow-derived stem 
cells. Therefore, BMP-4 activation has been related 
to pathways dependent or independent of Smads. 
These different findings may be due to the different 
lineage cell type, species, and culture conditions. 
Zuk, et al.35 (2011) did not observe any significant 
changes in Smad1/5/8 phosphorylation levels 
upon BMP-2 induction. Additionally, these authors 
observed that the removal of dexamethasone 
from the BMP-2 did not significantly change the 
mineralization capacity of ASCs from that measured 
when samples were induced with BMP-2 and OM 
containing dexamethasone. Such a finding would 
suggest that the lack of effect of BMP-2 was 
not due to any interference by the presence of 
dexamethasone.
Despite that the presence of BMP-2 in the 
osteogenic supplementation led to the highest 
expression of Smads, this protein did not increase 
the ALP activity at the peak of this enzyme, the 
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expression of osteonectin and osteocalcin mRNA, or 
the calcium deposition at the extracellular matrix, an 
indicator of osteoblast final maturation. Conversely, 
Dragoo, et al.8 (2003) observed that ASCs cultured 
with BMP-2 demonstrated more ALP and matrix 
calcification than the positive osteoblast control. 
Considering that both treatments (ASCs+OM and 
ASCs+OM+BMP2) led to similar effects in osteogenic 
differentiation, the effects of exogenous BMP-2 could 
be counterbalanced by the highest expression of 
endogenous BMP-4 and BMP-7. Herein, probably 
endogenous BMP-4 and BMP-7 pathways were 
independent of Smad activation, corroborating 
Seib, et al.22 (2009). There are a number of 
possible explanations for the reasons that ASCs 
had demonstrated similar osteogenic differentiation 
in the presence or absence of BMP-2, including the 
maturation of osteogenic progenitors during culture, 
emergence of a dominant cell type or spontaneous 
differentiation of MSCs into the osteoblasts22,24. 
Although a combination of these factors could be 
responsible for the results herein, endogenous BMPs 
production could be a critical factor in any of these 
scenarios.
CONCLUSIONS
We concluded that human ASCs expressed 
endogenous BMP-4 and BMP-7. Moreover, the 
supplementation of ASCs with BMP-2 did not increase 
the level of osteogenic markers in the initial (ALP 
activity), intermediate (osteonectin and osteocalcin), 
or final (calcium deposition) phases suggesting that 
the exogenous addition of BMP-2 did not improve 
the in vitro osteogenesis process of human ASCs.
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